Figure 1

Vaccine targeting mannose receptor polarizes dendritic cells to a Th1 cytokine phenotype. Monocyte-derived DCs from normal donor PBMCs (1a) or cancer patients (1b) were treated as described under Methods. (1a) Differential Th1-type cytokine production by DCs treated separately with vaccine (B11-hCGβ at 10 μg/ml) and TLR activating agents; (1b) Vaccine-specific DC-dependent Th1 cytokine induction in cancer patients.